Ross Moat was named Chief Operating Officer of Kiniksa Pharmaceuticals International, plc. As of November 6, 2026, Kiniksa Pharmaceuticals International, plc has reported 2 leadership change filings to the SEC under Item 5.02 of Form 8-K, from May 1, 2026 to October 22, 2026, naming 1 appointment and 2 departures (Form 8-K, October 22, 2026).
30 companies changed executives this week.
Companies that just changed executives, and the new executive. Before you unlock: the company, the change and what is inside. After: the executive named with their role, how to reach the company, and a person's email only when we found one.
| John Hancock Comvest Private Income Fund | named a new Chief Financial Officer | |
| Bain Capital Specialty Finance, Inc. | named a new Director | |
| Azora Therapeutics, Inc. (DE) | named a new Director | |
| LASE Corp. | named a new Director | |
| Century Communities, Inc. | named a new Executive Chairman |
Sell to companies like Kiniksa Pharmaceuticals International, plc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Kiniksa Pharmaceuticals International, plc reported changes in 2 filings among its directors and officers to the SEC on Form 8-K, Item 5.02, from 2026-05-01 to 2026-10-22. They name 2 people, with 1 appointment and 2 departures. Every row below is cited to the filing it comes from, and this page adds each new change as Kiniksa Pharmaceuticals International, plc files it.
Also on the record for Kiniksa Pharmaceuticals International, plc
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| July 29, 2026 | Stake report, Schedule 13G, by BlackRock, Inc. | 5.5% of the class | 5%+ stakes | Source |
| May 26, 2026 | Stake report, Schedule 13D/A, by Baker Bros. Advisors LP | 7% of the class | 5%+ stakes | Source |
| May 6, 2026 | Stake report, Schedule 13G/A, by FMR LLC | 14.8% of the class | 5%+ stakes | Source |
| March 27, 2026 | Stake report, Schedule 13G/A, by The Vanguard Group | — | 5%+ stakes | Source |
| March 6, 2026 | Stake report, Schedule 13G, by FMR LLC | 10.6% of the class | 5%+ stakes | Source |
| February 13, 2026 | Stake report, Schedule 13G/A, by Rubric Capital Management LP | 7.37% of the class | 5%+ stakes | Source |
| October 31, 2025 | Stake report, Schedule 13G/A, by The Vanguard Group | 7.04% of the class | 5%+ stakes | Source |
| July 17, 2025 | Stake report, Schedule 13G/A, by BlackRock, Inc. | 1% of the class | 5%+ stakes | Source |
| July 9, 2025 | Stake report, Schedule 13G/A, by RUBRIC CAPITAL MANAGEMENT LP | 9.24% of the class | 5%+ stakes | Source |
Selling to them or working with them? See who runs Kiniksa Pharmaceuticals International, plc now and the warning signs.
Free to see. No signup.
Keep reading
More on Kiniksa Pharmaceuticals International, plc and the records around it.
Kiniksa Pharmaceuticals International, plc elsewhere on the record
- 5%+ stake filings Jul 2026
- Who owns it
Companies that share a holder
- Baker Bros. Advisors LP also filed stake reports on 25 other companies: Madrigal Pharmaceuticals, Inc. (Nov 2026), Kodiak Sciences Inc. (Sep 2026), BeOne Medicines Ltd. (Sep 2026)
- Rubric Capital Management LP also filed stake reports on 32 other companies: ARDELYX, INC. (Aug 2026), Enovis Corporation (Aug 2026), MeiraGTx Holdings plc (Aug 2026)
- FMR LLC also filed stake reports on 761 other companies: ASPEN NEUROSCIENCE INC (Nov 2026), AVALO THERAPEUTICS INC (Nov 2026), BRAZE INC (Nov 2026)
Watch Kiniksa Pharmaceuticals International, plc
Get an email when Kiniksa Pharmaceuticals International, plc files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Kiniksa Pharmaceuticals International, plc?
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on Kiniksa Pharmaceuticals International, plc: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Kiniksa Pharmaceuticals International, plc covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
11 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Timeline
| Filed | In / out | Person | Role | Effective | Source |
|---|---|---|---|---|---|
| 2026-10-22 | In | Chief Operating Officer | 8-K, 2026-10-22 | ||
| 2026-05-01 | Out | Chief Strategy Officer | 8-K, 2026-05-01 | ||
| 2026-05-01 | Out | 8-K, 2026-05-01 |
Who leads Kiniksa Pharmaceuticals International, plc, as last reported?
For each role that changed in the filings below, the most recent change reported. A role that did not change in these filings is not listed.
- Chief Operating Officer: Ross Moat, appointed (filed 2026-10-22).
- Chief Strategy Officer: Eben Tessari, departure reported (filed 2026-05-01). No successor is named in these filings.
New leaders reset buying decisions — get the Full Report on Kiniksa Pharmaceuticals International, plc: who runs it, how the money works and what to watch, every claim linked to its source.
Get the Full ReportFind people with the same kind of experience as the Chief Operating Officer at Kiniksa Pharmaceuticals International, plc, with the record behind each one.
Find candidates like Chief Operating Officer at Kiniksa Pharmaceuticals International, plcEvery change, in the filing's words
Appointed: Ross Moat, Chief Operating Officer
On October 17, 2026, the Compensation Committee (the "Committee") of the Board of Directors of Kiniksa Pharmaceuticals International, plc (the "Company") appointed Ross Moat as President and Chief Operating Officer, effective immediately.
- Mr. Moat will continue to report to Sanj K. Patel, the Company's Chairman and Chief Executive Officer.
- In addition, effective January 1, 2027, the Committee approved increases in Mr. Moat's annual base salary and annual target bonus to $700,000 and 60% from $650,000 and 55%, respectively.
- Mr. Moat has served in varying capacities at the Company since June 2019, most recently as the Company's EVP, Chief Operating Officer.
- In his current position, Mr. Moat oversees the Company's commercial, clinical, regulatory and manufacturing operations.
- Mr. Moat's full biographical information is disclosed in the Company's definitive proxy statement on Schedule 14A filed with the Securities and Exchange Commission on April 16, 2026.
Departing: Eben Tessari, Chief Strategy Officer
On April 30, 2026, Eben Tessari informed Kiniksa Pharmaceuticals International, plc (the "Company") of his decision to resign as Chief Strategy Officer of the Company to pursue another executive position within the life sciences industry.
Departing: Eben Tessari
Mr. Tessari will leave the Company on May 15, 2026 and will become a consultant to the Company and an advisor to its Science and Research Committee.
- Mr. Tessari's decision to resign was not the result of any disagreement with the Company on any matter relating to the Company's operations, policies, or practices.
- Pursuant to a Consulting Agreement (the "Consulting Agreement") between Mr. Tessari and the Company, which will be effective as of May 15, 2026, Mr. Tessari will: (i) provide services to the Company related to strategic and operational matters and (ii) serve as a special advisor to the Company's Science and Research Committee (together, the "Services").
- The Consulting Agreement will have a term commencing on May 15, 2026 and ending on May 15, 2027, and may be renewed on the same terms and conditions for an additional one-year period if mutually agreed upon by the parties.
- The Consulting Agreement may be terminated by the Company or Mr. Tessari with prior written notice to the other party.
- Pursuant to the Consulting Agreement, Mr. Tessari will receive compensation of $450 per hour of Services performed, up to 20 hours per month, as well as reimbursement for reasonable pre-approved travel and out-of-pocket expenses incurred in performing the Services.
Tools for this story
Each opens in a new tab, filled in for Kiniksa Pharmaceuticals International, plc. With no account yet, you sign up free and land on the result.
Where this comes from
A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.
Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.